BioLineRx (BLRX) Non-Current Debt (2011 - 2025)

BioLineRx's Non-Current Debt history runs 12 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• On a quarterly basis, Non-Current Debt fell 50.21% year-over-year to $4.5 million in Q4 2025; TTM through Dec 2025 was $4.5 million, a 50.21% decrease from a year earlier, with the FY2025 full-year figure at $4.5 million, down 50.21% from the prior year.
• Non-Current Debt eased to $4.5 million in Q4 2025 per BLRX's latest filing, from $5.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $18.8 million in Q2 2024 and bottomed at $1.0 million in Q2 2021.
• The 5-year median for Non-Current Debt is $7.9 million (2023), against an average of $8.0 million.
• Across the five-year window, Non-Current Debt slumped 76.76% in 2021 and surged 121.19% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $1.0 million in 2021, then surged by 757.46% to $8.6 million in 2022, then decreased by 23.16% to $6.6 million in 2023, then jumped by 35.15% to $9.0 million in 2024, then slumped by 50.21% to $4.5 million in 2025.
• Per Business Quant, the three latest BLRX Non-Current Debt figures stand at $4.5 million (Q4 2025), $5.6 million (Q3 2025), and $6.7 million (Q2 2025).